Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05245539 · ClinicalTrials.gov registry record · Phase 1
Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia
A Phase 1 study of Schizophrenia and Blood Pressure, sponsored by Cerevel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 151
- Enrollment target
- 10
- Study locations
NCT05245539 is a Phase 1 study of Schizophrenia and Blood Pressure that has completed, run by Cerevel Therapeutics. The registered enrollment target is 151 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (31% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT05245539, a Phase 1 study of Schizophrenia and Blood Pressure, has completed, sponsored by Cerevel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 151 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this trial is to characterize the effects of 2 oral doses (over 8 weeks total) of CVL-231 on ambulatory blood pressure and heart rate in patients with stable schizophrenia.
Conditions Studied
Interventions
- DRUG CVL-231
Study Locations (10)
Arkansas
- Pillar Clinical Research LLC - Bentonville
- Woodland International Research Group LLC - ERG - PPDS - Little Rock
Illinois
- Uptown Research Institute LLC - Chicago
- Pillar Clinical Research LLC - Lincolnwood
Texas
- Community Clinical Research - Austin
- Pillar Clinical Research LLC - Richardson
California
- Collaborative NeuroScience Research, LLC - Torrance - Apex - PPDS - Long Beach
Florida
- Innovative Clinical Research, Inc - ClinEdge - PPDS - Miami
New Jersey
- Hassman Research Institute - Apex - PPDS - Marlton
Ohio
- Neuro-Behavioral Clinical Research, Inc. - North Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2022-01-24 |
| Est. Completion | 2022-11-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05245539
The ClinicalTrials.gov registry entry for NCT05245539 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (31% lower). The listed sponsor is Cerevel Therapeutics, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which CVL-231 is the first listed.
NCT05245539 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Arkansas, Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT05245539 about?
NCT05245539 is a clinical study titled "Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia". The purpose of this trial is to characterize the effects of 2 oral doses (over 8 weeks total) of CVL-231 on ambulatory blood pressure and heart rate in patients with stable schizophrenia.
What is the current status of trial NCT05245539?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 151 participants. The study started on 2022-01-24. Estimated completion is 2022-11-14.
What conditions does trial NCT05245539 study?
This clinical trial studies the following conditions: Schizophrenia, Blood Pressure.
What interventions are being tested in trial NCT05245539?
The interventions under investigation include: CVL-231 (DRUG).
Who is sponsoring clinical trial NCT05245539?
This trial is sponsored by Cerevel Therapeutics, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05245539 being conducted?
This trial has 10 study locations across Arkansas, California, Florida, Illinois, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.